Compare EDAP & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDAP | NTHI |
|---|---|---|
| Founded | 1979 | 2008 |
| Country | France | United States |
| Employees | N/A | 5 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.9M | 139.1M |
| IPO Year | 1998 | N/A |
| Metric | EDAP | NTHI |
|---|---|---|
| Price | $4.32 | $4.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | ★ $15.00 |
| AVG Volume (30 Days) | 30.0K | ★ 46.6K |
| Earning Date | 05-07-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,527,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.63 | N/A |
| 52 Week Low | $1.21 | $3.20 |
| 52 Week High | $5.05 | $12.99 |
| Indicator | EDAP | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 61.10 | 40.36 |
| Support Level | $3.18 | $4.49 |
| Resistance Level | $4.38 | $5.90 |
| Average True Range (ATR) | 0.26 | 0.45 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 67.39 | 23.33 |
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.